Shuttle Pharmaceuticals Inc (SHPH) - Net Assets
Based on the latest financial reports, Shuttle Pharmaceuticals Inc (SHPH) has net assets worth $2.25 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.48 Million) and total liabilities ($8.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SHPH asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.25 Million |
| % of Total Assets | 21.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2724.3 |
Shuttle Pharmaceuticals Inc - Net Assets Trend (2017–2025)
This chart illustrates how Shuttle Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore Shuttle Pharmaceuticals Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Shuttle Pharmaceuticals Inc (2017–2025)
The table below shows the annual net assets of Shuttle Pharmaceuticals Inc from 2017 to 2025. For live valuation and market cap data, see Shuttle Pharmaceuticals Inc (SHPH) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.25 Million | +217.91% |
| 2024-12-31 | $709.15K | -82.51% |
| 2023-12-31 | $4.06 Million | -47.18% |
| 2022-12-31 | $7.68 Million | +571.58% |
| 2021-12-31 | $-1.63 Million | +3.68% |
| 2020-12-31 | $-1.69 Million | -6256.38% |
| 2018-12-31 | $27.46K | +109.66% |
| 2017-12-31 | $-284.35K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shuttle Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4501532200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.00 | 0.00% |
| Other Components | $48.55 Million | 2153.71% |
| Total Equity | $2.25 Million | 100.00% |
Shuttle Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Shuttle Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Marston’s PLC
LSE:MARS
|
$3.87 Million |
|
Trugolf Inc
NASDAQ:TRUG
|
$3.88 Million |
|
Aeon Metals Ltd
AU:AML
|
$3.88 Million |
|
WOODPECKER.CO ZY -10
F:8FG
|
$3.88 Million |
|
Property Franchise Group PLC
LSE:TPFG
|
$3.86 Million |
|
KD Corporation
KQ:044180
|
$3.86 Million |
|
iSpecimen Inc
NASDAQ:ISPC
|
$3.86 Million |
|
Octopus Renewables Infra Trust
LSE:ORIT
|
$3.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shuttle Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 709,152 to 2,254,446, a change of 1,545,294 (217.9%).
- Net loss of 11,721,669 reduced equity.
- New share issuances of 9,489,673 increased equity.
- Other factors increased equity by 3,777,290.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.72 Million | -519.94% |
| Share Issuances | $9.49 Million | +420.93% |
| Other Changes | $3.78 Million | +167.55% |
| Total Change | $- | 217.91% |
Book Value vs Market Value Analysis
This analysis compares Shuttle Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.50x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.02 | $0.69 | x |
| 2018-12-31 | $0.00 | $0.69 | x |
| 2020-12-31 | $-0.12 | $0.69 | x |
| 2021-12-31 | $-0.12 | $0.69 | x |
| 2022-12-31 | $0.74 | $0.69 | x |
| 2023-12-31 | $0.25 | $0.69 | x |
| 2024-12-31 | $0.07 | $0.69 | x |
| 2025-12-31 | $1.38 | $0.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shuttle Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -519.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 4.65x
- Recent ROE (-519.94%) is above the historical average (-539.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-185.16K |
| 2018 | -2280.52% | 0.00% | 0.00x | 22.63x | $-628.88K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-636.70K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-989.32K |
| 2022 | -65.07% | 0.00% | 0.00x | 1.13x | $-5.76 Million |
| 2023 | -162.55% | 0.00% | 0.00x | 1.47x | $-7.00 Million |
| 2024 | -1289.54% | 0.00% | 0.00x | 3.53x | $-9.22 Million |
| 2025 | -519.94% | 0.00% | 0.00x | 4.65x | $-11.95 Million |
Industry Comparison
This section compares Shuttle Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $236,113,024
- Average return on equity (ROE) among peers: -47.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shuttle Pharmaceuticals Inc (SHPH) | $2.25 Million | 0.00% | 3.65x | $3.87 Million |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clini… Read more